Soligenix's SGX301 shows sustained benefit in late-stage lymphoma study

• Additional data from Phase 3 Flash trial evaluating Soligenix's (SNGX +6.4%) SGX301 (synthetic hypericin) in patients with cutaneous T-cell lymphoma (CTCL), has reinforced positive primary endpoint treatment response demonstrated in treatment cycle 1, with further improved response rates in Cycle 3.
• 49% of patients who received SGX301 for 18 weeks, demonstrated a 50% or greater reduction in their lesion score compared to 40% of patients demonstrating such a reduction after completing 12 weeks of SGX301 treatment in Cycle 2.
• Continued analysis showed that 12 weeks of treatment is equally effective on both patch (response 37%) and plaque (response 42%) lesions when compared to Cycle 1 placebo lesion responses.
• Soligenix previously announced the FLASH study achieved statistical significance in its primary endpoint over the first 6-week treatment cycle (Cycle 1).
• After the subsequent additional 6-week treatment in the Cycle 2, the response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold (40% compared to placebo).
• https://seekingalpha.com/news/3624927-soligenixs-sgx301-shows-sustained-benefit-in-late-stage-lymphoma-study